Salix Pharmaceuticals (SLXP -4.8%) slides after Auriga downgrades the stock to Hold from Buy and lowers its price target to $51 from $54. The firm says SLXP shares appear to have already priced in upside from the potential approval of developmental drugs Relistor and Crofelemer. Auriga had upgraded shares to Buy only six weeks ago.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Wed, 4:39PM)
at Investor's Business Daily (Mon, 6:54PM)
at Benzinga.com (Mon, 2:41PM)
at Investor's Business Daily (Feb 20, 2015)
at Investor's Business Daily (Feb 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs